LONDON, Jan 16 (Reuters) - Shares of Novo Nordisk rose 7% on Friday, touching their highest level since September, and were among the top gainers in Europe, ahead of U.S. prescription data expected from analysts on the Danish drugmaker's Wegovy pill.
The weightloss pill was made available to U.S. patients from January 5, following approval by the U.S. Food and Drug Administration last month.
The share price reaction is driven by encouraging early scripts for Wegovy Pill in the United States, said Sydbank analyst Soren Lontoft Hansen.
(Reporting by Bhanvi Satija in London and Elviira Luoma in Gdansk; Editing by Joe Bavier)
